Industries de la santé
$100 billion of revenues up for grabs for drug manufacturers by 2020 as patents for key biologics expire
14 Mars 2017
Although complexities inherent in biological drug manufacturing are creating barriers for further expansion of the biosimilars market, imminent patent expiries of key biologics are set to create new opportunities for biosimilar manufacturers, according to business intelligence provider GBI Research. |Adam Bradbury and Rishikesh Mandilwar, Analysts at GBI Research and co-authors of the...
Plus d'articles...
- I.CERAM : Présentation de son implant sternal
- Onxeo présente ses résultats annuels pour l'exercice 2016 et ses perspectives pour l'année 2017
- French pharmaceutical market to stagnate as government embraces generics to cut healthcare expenditure
- DBV Technologies : De nouvelles données présentées au Congrès 2017 de l'AAAAI